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Chemical tools to monitor drug-target engagement of endogenously expressed protein
kinases are highly desirable for preclinical target validation in drug discovery. Here, we
describe a chemical genetics strategy to selectively study target engagement of endogenous
kinases. By substituting a serine residue into cysteine at the DFG-1 position in the ATP-
binding pocket, we sensitize the non-receptor tyrosine kinase FES towards covalent labeling
by a complementary fluorescent chemical probe. This mutation is introduced in the endo-
genous FES gene of HL-60 cells using CRISPR/Cas9 gene editing. Leveraging the temporal
and acute control offered by our strategy, we show that FES activity is dispensable for
differentiation of HL-60 cells towards macrophages. Instead, FES plays a key role in neu-
trophil phagocytosis via SYK kinase activation. This chemical genetics strategy holds promise
as a target validation method for kinases.
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Protein kinases comprise a 518-membered family of enzymesthat play essential roles in intracellular signaling processes.They transfer a phosphate group from ATP to specific
amino acid residues in proteins, thereby modulating protein
activity, localization and protein–protein interactions1,2. Protein
kinases are involved in many cellular functions, including pro-
liferation, differentiation, migration, and host–pathogen interac-
tions. Kinases are also an important class of drug targets for the
treatment of cancer3. However, current FDA-approved kinase
inhibitors are designed to target only <5% of the entire kinome4
and therapeutic indications outside oncology are vastly
underrepresented5,6. These so-far untargeted kinases thus offer
great opportunities for the development of novel molecular
therapies for various diseases. The non-receptor tyrosine kinase
feline sarcoma oncogene (FES), subject of the here presented
study, is a potential therapeutic target for cancer and immune
disorders7–9.
FES, together with FES-related kinase (FER), constitutes a
distinct subgroup within the family of tyrosine kinases, defined by
their unique structural organization. FES is able to form oligo-
mers via its F-Bin-Amphiphysin-Rvs (F-BAR) domain, which
drives translocation from the cytosol to the cell membrane10,11. In
addition, FES possesses a Src Homology 2 (SH2) domain that
binds phosphorylated tyrosine residues and functions as protein
interaction domain12,13. The catalytic domain of FES is located on
its C-terminal end. Phosphorylation of Y713 in the activation
loop of FES is a prerequisite for its kinase activity and can occur
either via autophosphorylation or phosphorylation by Src family
kinases14,15. FES has a restricted expression pattern and is found
in neuronal, endothelial and epithelial cells. Its expression levels
are highest in cells of hematopoietic origin, especially those in the
myeloid lineage16. Most of the physiological processes of FES
have been studied in macrophages17,18 or mast cells19, but far less
is known about its role in other terminally differentiated myeloid
cells, such as neutrophils.
The successful development of new kinase-targeting drugs
strongly depends on our understanding of their underlying
molecular and cellular mechanism of action, i.e. the preclinical
target validation20. The physiological function of many kinases
remains, however, poorly characterized and their direct protein
substrates are often unknown. Genetic models (congenital dele-
tion or expression of kinase-dead variants) may be used to study
these questions. For example, FES knockout mice revealed a role
for FES in leukocyte migration21,22 and the release of inflam-
matory mediators17. However, long-term, constitutive genetic
disruption of kinases can result in compensatory mechanisms
that counteract defects in cellular signaling. For example, mice
lacking both FES and FER have more pronounced defects in
hematopoiesis than counterparts lacking only one of these kina-
ses, which may indicate that these related kinases may compen-
sate for each other’s loss23. Long-term, permanent genetic models
are therefore poorly suited to study rapid and dynamic signaling
processes24,25. In addition, phenotypic differences between
independently generated knockout animals are not uncommon,
as was the case for two independently developed fes−/− mice17,26.
A complementary approach is the use of inhibitors to modulate
kinase activity in an acute and temporal fashion. This approach
more closely resembles therapeutic intervention, but the available
pharmacological tools, especially for non-validated kinases, often
suffer from a lack of selectivity24,27. Currently, there are no sui-
table FES inhibitors available for target validation studies, because
they either lack potency or selectivity, and all cross-react with
FER7,28.
A key step in the target validation process consists of obtaining
proof of target engagement, which is essential to correlate inhi-
bitor exposure at the site of action to a pharmacological and
phenotypic readout29. Information about kinase engagement is
also useful for determining the dose required for full target
occupancy without inducing undesired off-target activity30.
Chemical probes that make use of a covalent, irreversible mode of
action are ideally suited to study target engagement29. Incor-
poration of reporter tags enable target visualization (e.g. fluor-
ophores) or target enrichment and identification (e.g. biotin). In
the field of kinases, reported chemical probes either target a
conserved active-site lysine residue in a non-selective fashion31 or
non-catalytic cysteine residues in the ATP-binding pocket32,33.
The first class of kinase probes lacks the selectivity required for
cellular target engagement studies. On the other hand, the
majority of kinases, including FES, do not possess targetable
cysteine residues in the catalytic pocket34.
Garske et al. previously introduced the elegant concept of
covalent complementarity: the use of an engineered kinase in
which the gatekeeper amino acid residue is mutated into a
cysteine, combined with electrophilic ATP analogs to study target
engagement35. Other positions in the kinase active site have also
been investigated36–38, but secondary mutations were required to
improve cysteine reactivity or compound selectivity and potency.
Of note, all studies relied on transient or stable overexpression of
the mutant kinase, rather than physiological model systems with
endogenous expression levels. Since overexpression of kinases is
known to disrupt physiological intracellular signaling cascades39,
there is a need for target validation methods that visualize specific
endogenous kinase activity and its engagement by small mole-
cules without perturbing normal cellular processes. Inspired by
these established and emerging concepts, we describe herein a
chemical genetics strategy to profile acute target engagement of
FES kinase by a complementary, mutant-specific chemical probe.
Results
Chemical genetics strategy for target engagement studies. The
key feature of the chemical genetics strategy is the combination of
an engineered, mutant kinase with the design and application of
complementary, covalent inhibitors (Fig. 1a). The ATP-binding
pocket of the kinase of interest is sensitized towards pharmaco-
logical inactivation using complementary probes by substituting
an amino acid for a cysteine residue. The mutant is biochemically
characterized to verify that this mutation minimally affects kinase
function (Fig. 1b, step 1). Subsequently, complementary electro-
philic inhibitors are designed to covalently react with this cysteine
(Fig. 1b, step 2). Covalent, irreversible inhibitors can have several
advantages over reversible compounds, such as sustained target
occupancy, lower susceptibility to competition by high intracel-
lular ATP concentrations and a pharmacodynamic profile that is
dependent on the target’s de novo protein synthesis rate40. The
inhibitor will have far lower potency on the wild-type (WT)
kinase, which does not possess a nucleophilic residue in its active
site, thereby making the inhibitor mutant-specific. An important
feature of our strategy is that the corresponding cysteine point
mutation is introduced endogenously in a relevant cell line using
CRISPR/Cas9 gene editing (Fig. 1b, step 3). This circumvents the
use of cellular overexpression systems, which may disturb the
intrinsic balance of the kinase signaling network, leading to
compensatory effects and other artefacts in cellular function39.
Importantly, the covalent binding mode of the inhibitor enables
target engagement profiling by acting as a chemical probe and its
ligation handle can be further functionalized with reporter tags
for visualization by SDS-PAGE (fluorophore) or identification of
the bound targets by mass spectrometry (biotin) (Fig. 1b, step 4).
Since this approach allows acute inactivation of kinases with high
specificity, it can be employed to study kinase function and
thereby aid in its validation as therapeutic target (Fig. 1b, step 5).
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Biochemical characterization of engineered FES kinases. To
introduce a cysteine residue at an appropriate position in the
ATP-binding pocket of FES, we inspected the reported crystal
structure of FES with reversible inhibitor TAE684 (compound 1)
(PDB: 4e93)28. We selected nine active-site residues situated in
proximity of the bound ligand (Fig. 2a) and generated the
respective cysteine point mutants by site-directed mutagenesis on
truncated human FES (SH2 and kinase domain, residues
448–822) fused to a N-terminal His-tag. The WT protein and the
mutants were recombinantly expressed in Escherichia coli (E.
coli), purified using Ni2+-affinity chromatography and tested for
catalytic activity using a time-resolved fluorescence resonance
energy transfer (TR-FRET) assay (Fig. 2b). Four of the nine tested
mutants did not display any catalytic activity, including G570C
(located on P-loop) and G642C (hinge region). Three mutants
near the kinase hydrophobic backpocket (I567C, V575C, and
L638C) retained partial activity, whereas only two mutants
(T646C and S700C) displayed catalytic activity similar to FESWT.
Our attention was particularly drawn to the S700C mutant, which
involves the residue adjacent to the highly conserved DFG motif
(DFG-1). Since several other kinases (e.g. MAPK1/3, RSK1-4, and
TAK1) express an endogenous cysteine at DFG-1 that can be
targeted by electrophilic traps32, we chose to profile FESS700C in
more detail. The engineered kinase displayed identical reaction
progress kinetics (Fig. 2c) and similar affinity for ATP (KM= 1.9
μM for FESWT and KM= 0.79 μM for FESS700C; Fig. 2d and
Supplementary Fig. 1a).
To assess whether the introduced mutation affected substrate
recognition, a comparative substrate profiling assay was per-
formed using the PamChip® microarray technology. This assay is
based on the phosphorylation of immobilized peptides by purified
FES and detection using a fluorescently labeled anti-
phosphotyrosine antibody. Strikingly, the substrate profiles of
FESWT and FESS700C were completely identical (Fig. 2e, inset;
Supplementary Table 1), indicating that the S700C mutation did
not affect substrate recognition. Moreover, the absolute peptide
phosphorylation levels showed a strong correlation (R2= 0.95).
Comparison with the substrate profiles of five other non-receptor
tyrosine kinases (ABL, CSK, FGR, LYN, and SYK) confirmed that
a substantial number of peptides are FES-specific substrates
(Supplementary Fig. 2). Sequence analysis of the top 30 of highest
signal peptides revealed that FES prefers negatively charged
substrates with hydrophobic residues at positions −1 and +3 and
acidic residues at position −4, −3, and +1 relative to the tyrosine
phosphorylation site (Fig. 2f). These results are in line with a
previous study that reported on FES substrate recognition41.
Lastly, a modified PamChip array to measure phosphopeptide
binding to the Src homology 2 (SH2) domain of FESWT and
FESS700C showed that the introduced mutation did not affect the
SH2 binding profile (Fig. 2g and Supplementary Table 2). In
short, the DFG-1 residue (Ser700) in the ATP-binding pocket of
FES was identified as an excellent position to mutate into a
nucleophilic cysteine, without affecting FES kinase activity,
kinetics, substrate recognition or SH2 binding profile.
Synthesis and characterization of complementary probes. The
reversible ligand TAE684 was used as starting point to develop a
complementary probe for FESS700C. To assess whether the
FESS700C was still sensitive to inhibition by TAE684, the protein
was incubated with various concentrations of TAE684 and its half
maximum inhibitory concentration (expressed as pIC50) was
determined. We found that TAE684 was a potent inhibitor both
on FESWT and FESS700C with pIC50 values of 8.1 ± 0.04 and 9.0 ±
0.02, respectively (Table 1; assay performed with 5 µM ATP).
According to the co-crystal structure of FESWT with TAE684
(PDB: 4e93) the isopropyl sulfone moiety is in the close proximity
of Ser700 at the DFG-1 position. Therefore, several derivatives of
TAE684 were synthesized, in which the R2-phenyl was sub-
stituted with an acrylamide group as electrophilic warhead
(Supplementary Methods). The acrylamide is hypothesized
to covalently interact with the engineered cysteine, but not with
the serine of the WT protein. Since the strategy aims at exclu-
sively inhibiting mutant but not WT FES, the piperidine-
piperazine group was removed as it forms water-mediated
hydrogen bonds with hinge region residues and contributes
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Fig. 1 Chemical genetics strategy to visualize kinase activity and target engagement. a General strategy involving mutagenesis of a kinase DFG-1 residue
into a nucleophilic cysteine accompanied by mutant-specific covalent inhibitor design. A non-selective, reversible inhibitor is modified with an acrylamide
electrophile to covalently react to the introduced cysteine, along with an alkyne ligation handle for (bioorthogonal) conjugation to reporter tags using click
chemistry. The mutation is introduced in a relevant cell line using CRISPR/Cas9 gene editing in order to study the kinase in an endogenous expression
system. b Schematic workflow for application of mutant-specific, complementary probes in target engagement and target validation studies.
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to ligand affinity28. The pIC50 values of compound 2–6 are listed
in Table 1 (dose-response curves in Supplementary Fig. 1,b–f).
Removal of the piperidine-piperazine group (compound 2)
resulted in a modest reduction in potency on FESWT and
FESS700C. Introduction of an acrylamide at the meta-position of
the phenyl ring (compound 3) further decreased affinity for
FESWT, but also led to significant loss in activity on the FESS700C
mutant. Moving the acrylamide to the ortho-position resulted in
compound 4, which exhibited excellent potency on FESS700C
(pIC50= 8.4 ± 0.03), whereas a major reduction in potency on
FESWT (pIC50= 5.7 ± 0.21) was found, resulting in an apparent
selectivity window of 238-fold. We substituted the acrylamide
with a propionyl amide (compound 5) to confirm its important
role in binding to FESS700C. In line with the proposed mode of
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Next, we performed a docking study with compound 4 in
FESS700C (Fig. 3a). The binding mode of 4 resembled the original
binding pose of TAE684 and could explain the observed
structure-activity relationships. Catalytic lysine residue 590
interacts with the amide carbonyl, ideally positioning the warhead
on the ortho-position, but not meta-position, to undergo a
Michael addition with the engineered cysteine. The binding pose
also revealed a suitable position to install an alkyne moiety on the
scaffold of compound 4 to develop a two-step chemical probe for
target engagement studies. This led to the synthesis of probe 6
(hereafter referred to as WEL028) with an ortho-acrylamide and
alkoxyalkyne, which displayed a similar potency profile as 4 with
strong inhibition of FESS700C (pIC50= 8.4 ± 0.03) but not FESWT
(pIC50= 5.0 ± 0.37) (Fig. 3b). The mutant-specific inhibition
profile was additionally verified using the orthogonal PamChip®
microarray assay (Fig. 3c). To confirm that WEL028 undergoes
Michael addition to cysteine 700, we analyzed the WEL028-
FESS700C complex in more detail using mass spectrometry.
Recombinant FESS700C was incubated with WEL028, digested to
peptide fragments with trypsin and subsequently analyzed by LC-
MS/MS to confirm covalent addition of WEL028 to Cys700
(Fig. 3d and Supplementary Fig. 3).
Cys700 is located directly adjacent to the highly conserved
DFG motif. A substantial number of kinases also harbors a native
cysteine at this position, which might have implications for the
kinome-wide selectivity of WEL02840. We therefore assessed the
selectivity using the SelectScreen™ screening technology in a panel
of 380 wild-type, mammalian kinases including all kinases with a
native cysteine residue at any position in the active site. The
assays were performed at a single dose of 1 μM with 1 h of
preincubation to identify the full spectrum of potential off-target
kinases (Supplementary Fig. 4). Out of the 380 tested kinases,
26 showed >50% inhibition under these conditions, meaning
that WEL028 exhibited a >100-fold selectivity window against the
residual 354 kinases (93% of tested kinases, Fig. 3e). Subsequently,
dose-response experiments were performed for a representative
selection of kinases showing >50% inhibition in the initial
screen (Supplementary Table 3 and Supplementary Fig. 5). In
short, WEL028 was identified as a complementary two-step probe
for engineered FESS700C that does not label FESWT or FER and
has a sufficient selectivity profile over other kinases for our
purposes.
Target engagement studies with one-step probe WEL033. Next,
a one-step fluorescent probe for FESS700C was synthesized to
facilitate visualization of target engagement: a Cy5-conjugated
analog of WEL028 termed WEL033 (Fig. 4a). WEL033 dose-
dependently labeled recombinantly expressed full-length
FESS700C but not FESWT in HEK293T cell lysate (Fig. 4b).
Similar results were obtained using two-step labeling of WEL028-
treated lysate clicked to Cy5-azide in vitro (Supplementary
Fig. 6a, b). Complete labeling was achieved within 15min and this
labeling was stable up to 60 min (Supplementary Fig. 6c).
Fluorescent labeling of FESS700C was observed regardless of its
autophosphorylation state, suggesting that WEL033 covalently
binds to both catalytically active and inactive FES (Supplementary
Fig. 7a). Interestingly, introduction of a secondary K590E muta-
tion abolished labeling by WEL033 (Fig. 4c). This could indicate
that Lys590 is essential for covalent binding of WEL028 to the
FES active site, possibly by coordination of Lys590 that positions
the acrylamide warhead to undergo covalent addition to Cys700
as predicted by docking studies (Fig. 3a).
To visualize target engagement of FESS700C, a competitive
binding assay was performed with WEL033 in lysates over-
expressing full-length FESS700C. Two inhibitors (TAE684 and
WEL028) were able to prevent the labeling of FESS700C in a dose-
dependent manner (pIC50= 7.6 ± 0.06 and pIC50= 7.9 ± 0.06,
respectively; Fig. 4d, e). Of note, we found that our complemen-
tary probes could also be used to visualize target engagement on
other kinases with the DFG-1 residue mutated into a cysteine,
such as FERS701C, LYNA384C, PTK2G536C, and PAK4S457C
(Supplementary Figs. 8 and 9, Supplementary Table 4 and
Supplementary Note 1).
Time-dependent displacement experiments were performed to
study the mode of action of TAE684 and WEL028 (Supplemen-
tary Fig. 7b, c). After inhibitor incubation at their respective IC80
concentrations, labeling of FESS700C activity by WEL033 recovers
for TAE684 but not for WEL028, indicating a reversible and
irreversible mode of action for these compounds, respectively. In
line with these results, inhibitor washout experiments using
dialysis also showed sustained inhibition by WEL028 but not
TAE684 (Supplementary Fig. 7d–g). Of note, the increased
labeling intensities with TAE684-treated protein might be due to
enhanced stability of the protein as commonly observed for
molecular chaperones42. Thus, gel-based probe labeling experi-
ments using lysates of cells expressing full-length engineered
FESS700C is a valuable orthogonal method to standard biochem-
ical assays using purified, truncated proteins.
Subsequently, it was investigated whether WEL028 could also
engage FESS700C in living cells. To this end, HEK293T cells
overexpressing FESWT or FESS700C were incubated with various
concentrations of WEL028, after which cells were harvested and
lysed. WEL028-labeled proteins were then visualized using click
chemistry. Dose-dependent labeling of FESS700C was observed
(Fig. 4f, g), which indicates that WEL028 is cell-permeable and
can serve as a two-step probe in living cells. Of note, a
concentration of 100 nM WEL028 was sufficient to fully block
the labeling of FESS700C. Autophosphorylation of Tyr713 on the
activation loop of FES is a hallmark for its kinase activity14,43.
Consequently, immunoblot analysis using a phospho-specific
antibody for pY713 revealed that WEL028 (100 nM) fully
abolished autophosphorylation of FESS700C but not FESWT
(Fig. 4h, i). This indicates that the target engagement as measured
by gel-based probe labeling assay correlates with the functional
Fig. 2 Design and characterization of FES cysteine point mutants. a Location of mutated active-site residues (green) in FES crystal structure with bound
reversible inhibitor TAE684 (PDB code: 4e93). b Activity of recombinantly expressed FES mutants compared to WT, determined as relative amount of
phosphorylated peptide substrate after 60min incubation using TR-FRET assay. c Reaction progress kinetics for FESWT and FESS700C. d Determination of
ATP KM for FESWT and FESS700C. Enzyme reactions in TR-FRET assay were performed with ULight-TK peptide (50 nM) and ATP (b, c: 100 µM, d: variable)
and quenched (b, d: after 60min, c: variable). e Peptide phosphorylation substrate profile for FESWT and FESS700C as determined in PamChip® microarray.
Peptides were filtered for those with ATP-dependent signal and log2 of signal intensity >3. The peptide substrates were identical for FESWT and FESS700C
(Venn diagram, inset). f Preferred substrate consensus sequence based on FESWT substrate profile. Illustration was rendered using Enologos (http://www.
benoslab.pitt.edu). g SH2 domain binding profile for FESWT and FESS700C as determined in PamChip® microarray. Peptides with non-specific antibody
binding were excluded. The peptide SH2 binding partners were identical for FESWT and FESS700C (Venn diagram, inset). Data represent means ± SEM
(n= 3). Statistical analysis: ANOVA with Holm–Sidak’s multiple comparisons correction: *** P < 0.001; NS if P > 0.05. Source data are provided as a Source
Data file.
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Table 1 Inhibitory potency of synthesized TAE684 derivatives against FESWT and FESS700C.
Compound R1 R2 pIC50 FESWT pIC50 FESS700C Apparent fold selectivity
1 (TAE684) 8.1 ± 0.04 9.0 ± 0.02 8.6
2 H 7.3 ± 0.06 7.8 ± 0.04 2.5
3 H 6.5 ± 0.06 6.3 ± 0.06 0.65
4 H 5.7 ± 0.21 8.4 ± 0.03 238
5 H < 5 5.2 ± 0.08 ND
6 (WEL028) 5.0 ± 0.37 8.4 ± 0.03 232
Half maximal inhibitory concentrations (expressed as pIC50) determined on recombinantly expressed FESWT and FESS700C in a TR-FRET assay with 5 µM ATP. Apparent fold selectivity was calculated as
IC50 on FESWT divided by IC50 on FESS700C. Data represent means ± SD; n= 3. ND: not determined. Source data are provided as a Source Data file and complete dose–response curves can be found in
Supplementary Fig. 1.
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activity of FESS700C as determined in the biochemical and
immunoblot assays.
CRISPR/Cas9 gene editing for visualization of endogenous
FES. To obtain a physiologically relevant model system for
studying target engagement and avoid transient overexpression,
CRISPR/Cas9 gene editing was employed to introduce the S700C
mutation endogenously in the human HL-60 promyeloblast cell
line. Depending on the differentiation agent, HL-60 cells are
capable to undergo differentiation along the monocyte/macro-
phage (16 nM PMA, 48 h) as well as neutrophil lineage (1 µM
ATRA, 1.25% DMSO, 72–96 h) (Fig. 5a)44. In addition, HL-60
cells have been widely used to study neutrophil function45 as an
experimentally tractable alternative for primary neutrophils,
which have a short life-span and cannot be grown in cell
culture46.
To sensitize endogenously expressed FES in HL-60 cells to the
mutant-specific probe, a single guide (sg)RNA target was selected
with predicted site of cleavage in close proximity of the desired
mutation in exon 16 of the FES locus (Fig. 5b). In conjunction, a
single-stranded oligodeoxynucleotide (ssODN) homology-
directed repair (HDR) donor was designed, aimed to introduce
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Fig. 3 FESS700C is selectively and covalently inhibited by WEL028. a Proposed covalent binding mode of compound 4 to Cys700 in crystal structure of
FES (PDB code: 4e93). b In vitro inhibition profile of FESWT and FESS700C by WEL028 (TR-FRET assay, n= 3). c Inhibition profile of WEL028 (100 nM) on
FESWT and FESS700C on peptide substrates (PamChip® microarray, normalized to vehicle-treated control, n= 3). Scale shows residual activity from
minimum (0%, red) to maximum (100%, gray). dMS/MS-based identification of WEL028 covalently bound to Cys700. Precursor ion (m/z [M+ 2H]2+ =
689.2671) was fragmented and signature ions are shown. Precursor ion was not observed in vehicle-treated control. e In vitro selectivity profile of WEL028
(1 µM, 1 h preincubation) on 380 recombinant kinases, visualized as waterfall plot (each data point is an individual kinase; n= 2). Data represent means ±
SEM. Source data are provided as a Source Data file.
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Fig. 4 FESS700C can be visualized by fluorescent probe WEL033. a Design of fluorescent probe WEL033 (Cy5-conjugate). b Dose-dependent labeling of
full-length FESS700C by WEL033 in HEK293T cell lysate. c Labeling by WEL033 is specific, exclusive for FESS700C and dependent on catalytic lysine 590.
Lysates were preincubated with vehicle or 4 and labeled by WEL033 (250 nM). d, e Visualization of FESS700C target engagement by WEL028 and
TAE684. Lysate was preincubated with WEL028 or TAE684 and labeled by WEL033 (250 nM). Band intensities were normalized to vehicle-treated
control (n= 3). f, g WEL028 engages recombinantly expressed FESS700C in live cells. Transfected HEK293T cells were treated with WEL028 and labeled
proteins were visualized using click chemistry. Band intensities were normalized to highest concentration (n= 3). h, i WEL028 blocks FESS700C but not
FESWT autophosphorylation (visualized by immunoblot using anti-phospho-FES Y713). Band intensities were normalized to vehicle-treated control (n= 3).
Data represent means ± SEM. Statistical analysis: two-tailed t-test: *** P < 0.001. Source data are provided as a Source Data file.
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restriction enzyme recognition site to facilitate genotyping using a
restriction fragment length polymorphism (RFLP) assay. Of note,
the ssODN donor included also silent mutations to prevent
cleavage of the ssODN itself or recleavage of the genomic locus
after successful HDR (Fig. 5b). HL-60 cells were nucleofected
with plasmid encoding sgRNA and Cas9 nuclease along with the
ssODN donor, followed by single cell dilution to obtain clonal
cultures. We identified one homozygous S700C mutant clone out
of approximately 100 screened clones by RFLP analysis (Fig. 5c).
Sanger sequencing verified that the mutations had been
successfully introduced without occurrence of undesired deletions
or insertions (Fig. 5d). No off-target cleavage events were found
in a predicted putative off-target site (Supplementary Table 5 and
Supplementary Fig. 10).
Comprehensive biochemical profiling of FESS700C showed no
functional differences compared to FESWT in any of the in vitro
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assays (Fig. 2). In addition, we validated that HL-60 FESS700C cells
differentiated into macrophages or neutrophils in an identical
fashion as WT HL-60 cells. The percentage of differentiated cells
after treatment with differentiation agents was quantified by
monitoring surface expression of CD11b, a receptor present on
HL-60 macrophages and neutrophils but not on non-
differentiated HL-60 cells (Fig. 5e)47. No significant differences
were observed between WT and FESS700C HL-60 cells. In line with
this observation, WT and mutant cells undergoing differentiation
demonstrated a similar decrease in proliferation (Fig. 5f). Upon
differentiation along the macrophage lineage, HL-60 FESS700C
cells acquired a typical monocyte/macrophage morphology (e.g.
adherence to plastic surfaces, cell clumping and cellular elonga-
tion) comparable to WT cells (Supplementary Fig. 11). In a
similar fashion, HL-60 FESS700C cells differentiated into neutro-
phils acquired the ability to induce a respiratory burst upon PMA
stimulation, a characteristic phenotype of functional neutrophils
(Supplementary Fig. 12,e, f). To confirm that the mutant HL-60
cell line exhibited minimal transcriptional alterations compared to
parental WT cell line (e.g. due to clonal expansion), we performed
a targeted transcriptomics analysis using the TempO-Seq
technology (Fig. 5g)48. Only seven out of 21112 of the identified
transcripts (0.03%) were significantly altered in FESS700C
compared to WT HL-60 macrophages, which indicates that
introduction of this mutation minimally disturbs gene expression.
Notably, none of these genes are known to be involved in myeloid
differentiation.
Next, cell lysates of macrophages or neutrophils derived from
WT and FESS700C HL-60 cells were incubated with fluorescent
probe WEL033 to visualize endogenous FES (Fig. 5h). In-gel
fluorescence scanning of the WEL033-labeled proteome of
FESS700C HL-60 neutrophils and macrophages revealed a band
at the expected MW of FES (~93 kDa), which was absent in WT
HL-60 cells. This fluorescent band was less prominent in non-
differentiated HL-60 FESS700C cells, likely due to lower FES
expression levels prior to differentiation (Fig. 5h, anti-FES
immunoblot). Of note, WEL033 labeled a number of additional
proteins (MW of ~200, ~55 and ~40 kDa, respectively) at the
concentration used for FES detection (1 µM). In short, these
results demonstrate that endogenously expressed engineered FES
can be visualized using complementary chemical probes.
Cellular target engagement in differentiating HL-60 cells. FES
was previously reported as an essential component of the cellular
signaling pathways involved in myeloid differentiation49,50.
However, most of these studies relied on the use of over-
expression, constitutively active mutants, or antisense-based
knockdown of FES. In addition, it remains unclear whether this
role of FES is dependent on its kinase activity. To revisit this
question with pharmacological tools, it is key to establish which
concentration of inhibitor is minimally required to fully inhibit
the target in an endogenous setting. To this end, we tested
whether WEL028 inhibited endogenously expressing FESS700C
HL-60 cells at 100 nM and 1 µM during PMA-induced differ-
entiation towards macrophages (Fig. 6a; Supplementary Fig. 13).
Cells were harvested and lysed, followed by labeling of residual
active FESS700C by WEL033, which revealed full target engage-
ment of engineered FES at a concentration of 100 nM WEL028
(Fig. 6b), with only two prominent off-targets (~150 and ~40
kDa). At a higher concentration of 1 µM, WEL028 was sub-
stantially less selective (Fig. 6a) and inhibited the labeling of
multiple proteins.
The percentage of differentiated cells after treatment with the
differentiation agent was quantified by monitoring surface
expression of CD11b47. Strikingly, despite complete target
engagement of FESS700C at 100 nM WEL028 (Fig. 6b), the
percentage of CD11b-positive cells was minimally affected
(Fig. 6c-d). Cell proliferation, an indirect hallmark of differentia-
tion, was decreased to identical levels for FESS700C HL-60 cells
treated with vehicle or 100 nM WEL028 (Fig. 6e). Accordingly,
FESS700C HL-60 cells treated with 100 nM WEL028
acquired macrophage morphology (e.g. adherence to plastic
surfaces, cell clumping and cellular elongation) comparable to
vehicle-treated controls (Supplementary Fig. 11). Together, these
results show that complete FES inhibition does not affect PMA-
induced differentiation of HL-60 cells into macrophages,
suggesting that FES activity is dispensable for this process. In a
similar fashion, FES activity was found to be dispensable for
differentiation of HL-60 cells into functional neutrophils
(Supplementary Fig. 12).
Remarkably, FESS700C cells undergoing PMA-induced differ-
entiation in presence of a higher concentration of WEL028 (1
µM) completely failed to express CD11b, exhibited a less
pronounced decrease in proliferation and displayed phenotypic
characteristics similar to non-differentiated cells (Fig. 6c–e and
Supplementary Fig. 11). Competitive probe labeling experi-
ments revealed multiple WEL028 off-targets at 1 µM (Fig. 6a),
which suggested that the observed block in differentiation
might be due to off-target effects. A beneficial feature of the
used chemical genetic strategy is that WT cells can account for
these off-targets. Indeed, 1 µM WEL028 had similar effects on
CD11b surface expression, proliferation and morphology of
WT HL-60 cells subjected to differentiation (Fig. 6c–e and
Supplementary Fig. 11). This verifies that the functional effects
of WEL028 at 1 µM can indeed be attributed to off-target rather
than on-target effects.
Fig. 5 Visualization of endogenous FESS700C in CRISPR/Cas9-edited HL-60 cells. a HL-60 cells can differentiate into macrophages upon treatment with
phorbol 12-myristate 13-acetate (PMA) for 48 h or into neutrophils with all-trans-retinoic acid (ATRA, 1 µM) and DMSO (1.25%) for 72–96 h. b CRISPR/
Cas9 gene editing strategy. Selected sgRNA (bold blue) directs Cas9 to cleave at predicted site (red triangle). A ssODN homology-directed repair (HDR)
donor template (red) flanks introduced mutations with 80 bp homology arms. The S700C mutation generates a BglII restriction site along with three silent
mutations (orange) to remove PAM sites. Of note, two of the three mutated PAM sites correspond to sgRNAs not used in this study. PAM: protospacer-
adjacent motif. c Restriction-fragment length polymorphism (RFLP) assay for identification of HL-60 FESS700C clone. Genomic region was amplified by PCR
and amplicons were digested with BglII. Expected fragment size after digestion: 365+ 133 bp. d Sanger sequencing traces of WT HL-60 cells and
homozygous FESS700C HL-60 clone. No deletions, insertions or undesired mutations were detected. e CD11b surface expression of HL-60 cells prior to and
after differentiation, analyzed by flow cytometry. Threshold for CD11b-positive cells was determined using isotype control antibody (n= 3). f Reduction in
proliferation upon differentiation is similar for WT and FESS700C cells. Proliferation ratio: cell number after differentiation divided by cell number before
differentiation (n= 3). g Transcriptome profile of WT and FESS700C HL-60 macrophages analyzed by TempO-Seq. Differentially expressed genes (shown
in black) were identified using following cut-offs: log2 of fold change FESS700C over WT HL-60 cells <−1 or > 1 with q-value < 0.05 (n= 3). h Endogenous
FES is visualized by WEL033 in differentiated HL-60 FESS700C cells. WT or FESS700C HL-60 cells promyeloblasts, macrophages or neutrophils were lysed,
followed by labeling with WEL033 (1 μM). FES expression increases upon differentiation (anti-FES immunoblot). Data represent means ± SEM. Statistical
analysis: two-tailed t-test with Holm-Sidak’s multiple comparisons correction: NS if P > 0.05. Source data are provided as a Source Data file.
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Quantitative label-free chemical proteomics was used to
identify the off-targets of WEL028 at this high concentration.
The WEL028-labeled proteome was conjugated to biotin-azide
post-lysis, followed by streptavidin enrichment, on-bead protein
digestion and peptide analysis using mass spectrometry. Sig-
nificantly enriched kinases in WEL028-treated samples compared
to vehicle-treated samples were designated as targets (Fig. 6f-g).
Identified off-targets included protein kinases harboring native
cysteines at the DFG-1 position (depicted in bold), as well as
several metabolic kinases (ADK, PFKL, PFKP, ADPGK, NME1,
PKM, PGK1), although the latter lack a DFG motif. Notably, the
off-target profile of WT and FESS700C HL-60 cells was identical
with the exception of FES, which was exclusively present in
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a limited number of off-targets, WEL028 can be effectively used
in target engagement and validation studies using WT and
FESS700C HL-60 cells.
Role for FES in neutrophil phagocytosis via SYK activation.
Next, we sought to apply our chemical genetics strategy to study
the role of FES in neutrophils, the first line of defense against
invading bacteria. They are recruited to the site of infection and
their primary function is to phagocytize and kill the pathogens.
Neutrophil phagocytosis is a complex process that occurs via (a
cross-talk of) various receptors, including pathogen-associated
molecular pattern (PAMP) receptors, Fcγ receptors (FcγRs) and
complement receptors (CRs)51 Since FES was previously reported
to regulate cell surface receptors, including TLR4 in macro-
phages52 and FcεRI in mast cells11,19, we wondered whether FES
might be involved in neutrophil phagocytosis. First, we confirmed
that treatment of live neutrophils with a low concentration of
WEL028 (100 nM, 1 h) resulted in complete and selective inhi-
bition of FES in the mutant cells (Fig. 7a-b). Partial inhibition of
two off-targets (~80% inhibition of ~150 kDa protein and ~10%
inhibition of ~40 kDa protein) in both WT and mutant cells was
observed (Fig. 7a). To identify these off-targets, cells were har-
vested and the WEL028-bound targets were identified using
chemical proteomics. FES was exclusively identified in FESS700C
cells, whereas GAK and MAPK1 were identified as the only two
enriched proteins in both WT and FESS700C neutrophils (Fig. 7c
and Supplementary Fig. 14). Notably, the molecular weight of
GAK (143 kDa) and MAPK1 (41 kDa) match the size of the two
fluorescent bands visualized on gel, and both proteins were pre-
viously identified as WEL028 targets in the kinome screen
(Supplementary Fig. 4). Taken together, these data indicated that
our chemical genetics strategy using WEL028 can be used to
study the role of FES in neutrophils.
To measure the phagocytic uptake by HL-60 neutrophils, a
flow cytometry-based assay with live GFP-expressing E. coli
was employed (Fig. 7d, e). Both WT and FESS700C neutrophils
effectively internalized bacteria, with identical phagocytic
indices. Control cells incubated on ice were included to
account for surface binding without internalization. Interest-
ingly, WEL028 at an adequate concentration (100 nM) for
complete and selective FES inactivation (Fig. 7a), reduced the
phagocytic index by 30–50% in FESS700C expressing cells, but
not in WT HL-60 neutrophils (Fig. 7d, e, i; Supplementary
Fig. 15). Since the off-targets GAK and MAPK1 are shared
among WT and FESS700C HL-60 neutrophils (Fig. 7a and
Supplementary Fig. 14), these results indicate that on-target
FES inhibition is responsible for the observed reduction in
phagocytosis of E. coli.
To gain insight in the molecular mechanisms of FES-
mediated phagocytosis, we examined the previously obtained
substrate profile in more detail (Fig. 2e, Supplementary
Table 1). A peptide of the non-receptor tyrosine kinase
ZAP70 was identified as prominent FES substrate. Incubation
with WEL028 abolished peptide phosphorylation by FESS700C,
but not FESWT (Fig. 7f). Although ZAP70 is predominantly
linked to immune signaling in T-cells, its close homologue SYK
is ubiquitously expressed in various immune cells, including
neutrophils46. Moreover, SYK is part of signaling pathways
linked to pathogen recognition and involved in bacterial
uptake by neutrophils53. The identified ZAP70 peptide
substrate shows high sequence similarity to its SYK counter-
part surrounding Y352 (Fig. 7f). To validate that SYK is a
downstream target of FES, SYK-V5 and FESS700C-FLAG were
co-transfected in U2OS cells. First, it was confirmed that
overexpression of FESS700C led to autophosphorylation of FES
at Y713, which was sensitive to WEL028 (Fig. 7g). Subsequent
immunoblot analysis using a SYK Y352 phospho-specific
antibody showed that SYK was phosphorylated in a FES-
dependent manner (Fig. 7g). In accordance, co-transfection of
SYK with a kinase-dead FESK590E variant abolished Y352
phosphorylation (Supplementary Fig. 16a). Of note, WEL028
did not inhibit SYK in the kinome screen (Supplementary
Fig. 4) and did not affect SYK pY352 levels upon co-
transfection with FESWT (Supplementary Fig. 16a) or in
absence of FES (Supplementary Fig. 16b). In addition,
immunoprecipitation against FESS700C using an anti-FLAG
antibody revealed a physical interaction between FES and SYK
as witnessed by immunoblot against the V5-tag of SYK
(Fig. 7h). Importantly, this interaction was dependent on the
activation status of FES, because WEL028 inhibited the co-
precipitation of SYK with FES. Taken together, these results
suggest that SYK Y352 is a direct substrate of FES.
To verify that endogenous SYK is also involved in phagocytic
uptake of E. coli by neutrophils, HL-60 neutrophils were
incubated with the potent SYK inhibitor R406. SYK inhibition
reduced phagocytosis to similar levels as observed for WEL028
(Fig. 7i). Of note, U-73122 and Cytochalasin D were taken
along as positive controls to verify that the phagocytosis is
mediated via phospholipase C gamma 2 (PLCγ2) and actin
polymerization, respectively51. Finally, we verified whether the
downstream signaling pathway of SYK was modulated in a
FES-dependent manner by using immunoblot analysis with
phospho-specific antibodies for SYK Y352, hematopoietic cell-
specific protein-1 (HS1) Y397 (an actin-binding protein) and
PLCγ2 Y1217. Indeed, a transient phosphorylation of SYK,
HS1, and PLCγ2 was observed, which peaked at 2 min after
incubation with bacteria (Supplementary Fig. 17). Treatment
with WEL028 completely blocked the phosphorylation of these
proteins (Fig. 7j) in FESS700C but not WT neutrophils,
confirming an on-target, FES-specific effect. As an
Fig. 6 Comparative target engagement profiling in WT and FESS700C HL-60 cells during macrophage differentiation. a, b Gel-based target engagement
profile of WEL028 on WT and FESS700C HL-60 cells treated during PMA-induced differentiation. Cells were pretreated with vehicle or WEL028 (100 or
1000 nM, 1 h) prior to induction of differentiation towards monocytes/macrophages with PMA (16 nM, 48 h). Medium was refreshed with growth medium
containing WEL028 and PMA after 24 h to maintain full FES inhibition. Lysates were post-labeled with WEL033 (1 µM, 30min, rt). Band intensities were
normalized to vehicle-treated control (n= 3). c, d CD11b surface expression analyzed by flow cytometry. Threshold for CD11b-positive cells was
determined using isotype control antibody. Histograms illustrate representative replicates of FESS700C cells (n= 3). e Proliferation of WT and FESS700C HL-
60 cells subjected to macrophage differentiation. Proliferation ratio: live cell number after differentiation divided by live cell number before differentiation
(n= 3). f Chemical proteomics-based identification of WEL028 kinase targets at 1 μM in FESS700C HL-60 cells undergoing differentiation towards
macrophages. Kinases with >2-fold enrichment compared to vehicle control (q < 0.05) were designated as targets. Values represent means of fold
enrichment (n= 3). g Heat map representation of WEL028 (1 µM) target engagement profile in WT and FESS700C HL-60 cells undergoing macrophage
differentiation, determined by chemical proteomics. Scale shows fold enrichment from minimum (2, white) to maximum (100, dark blue). Kinases with
native cysteine at DFG-1 position are shown in bold. All data represent means ± SEM. Statistical analysis: two-tailed t-test with Holm-Sidak multiple
comparisons correction: ***P < 0.001; *P < 0.05; NS if P > 0.05. Source data are provided as a Source Data file.
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independent, alternative genetic method to validate the role of
FES in this signaling pathway, we generated a FES knockout
HL-60 cell line (Supplementary Fig. 18, a–d and Supplemen-
tary Table 6). Notably, these FESKO cells maintained the ability
to differentiate into neutrophils (Supplementary Fig. 18e), but
showed severely impaired SYK, HS1, and PLCγ2 phosphoryla-
tion. Taken together, these results indicate that FES activity is
required for the activation of this signaling pathway in HL-60
neutrophils in response to E. coli infection.
Discussion
The field of chemical genetics has previously generated tools to
aid in kinase target validation54,55. An example is the powerful
“analog-sensitive” (AS) technology, where the gatekeeper residue
is changed into a less bulky residue, enabling the kinase of interest
to accommodate bulky ATP analogs in its active site56. However,
these analogs do not form covalent adducts with the kinase and
therefore do not allow visualization of target engagement. Fur-
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impaired catalytic activity. The suboptimal pharmacokinetic
properties of ATP analogs used in the AS technology limit their
applicability for in vivo target validation studies57. The concept of
“covalent complementarity” is based on mutagenesis of the
gatekeeper35 or gatekeeper+637 residue into a cysteine to func-
tion as nucleophile. Although this allows the development of
covalent probes for target engagement studies, a secondary
mutation in the active site was required to improve gatekeeper
cysteine reactivity or compound selectivity and potency35,36. This
is particularly challenging when moving to an endogenous model
system, since it would involve two independent CRISPR/Cas9
gene editing events to introduce these two mutations.
Here, we identified the DFG-1 residue as an excellent position
for introducing a nucleophilic cysteine to react with an acryla-
mide as a complementary warhead, with no need for secondary
point mutations to improve cysteine reactivity or inhibitor
selectivity. Furthermore, mutagenesis of the DFG-1 position into
a cysteine is functionally silent: it does not affect FES catalytic
activity nor its substrate recognition and SH2 domain binding
profile. FESS700C showed a minor increase in ATP-binding affi-
nity, but this difference in KM is unlikely to have any con-
sequences at physiologically relevant ATP concentrations,
which are typically in the millimolar range40. Although nearly
10% of all known kinases have a native DFG-1 cysteine residue,
many kinases harboring a DFG-1 cysteine showed limited or no
inhibition by WEL028 (Supplementary Fig. 4 and Fig. 7c), sug-
gesting that the choice of the chemical scaffold constitutes an
additional selectivity filter. An acrylamide group was selected as
the electrophile to react with the intended cysteine, since it
exhibits sufficient reactivity towards cysteines only when appro-
priately positioned for a Michael addition reaction and has
limited reactivity to other intracellular nucleophiles58. This
may additionally prevent non-specific interactions with targets
outside of the kinase cysteinome. Given the selectivity profile and
cellular permeability of WEL028, we postulate that the diami-
nopyrimidine scaffold is a useful addition to the toolbox of
covalent complementary probes applied in chemical genetic
strategies, which previously consisted of mainly quinazolines and
pyrazolopyrimidines35,37.
Previously reported chemical genetic methods relied on over-
expression systems that disturb signal transduction cascades39. In
contrast, a major benefit of our strategy lies in the control that our
method allows to exert over a biological system without dis-
turbing the cellular homeostasis. By changing a single base-pair in
the FES gene, we substituted a single atom (oxygen to sulfur) in
the endogenous protein. Yet, this allowed us to rationally design
and synthesize a chemical probe that visualizes and inhibits the
engineered kinase activity in human cells. Arguably, this minimal
change at the genome and protein level ensures that regulation at
transcriptional and (post)-translational level activity are mini-
mally disturbed. In fact, we could demonstrate that the mutant
protein activity, substrate preference and protein–protein inter-
actions were similar to the WT protein. Furthermore, WT and
mutant cells behaved similarly in various functional assays
Fig. 7 FES mediates E. coli phagocytosis by HL-60 neutrophils via SYK activation. a, b Complete FESS700C inhibition at 100 nM WEL028 in HL-60
neutrophils. Cells were differentiated into neutrophils (1 µM ATRA, 1.25% DMSO, 72–96 h), treated with WEL028 (100 nM, 1 h) and lysates were post-
labeled (1 µM WEL033). Band intensities normalized to vehicle-treated control (n= 3). c Identification of WEL028 (100 nM) kinase targets in FESS700C
HL-60 neutrophils using chemical proteomics. Kinases with >2-fold enrichment compared to vehicle control (q < 0.05) were designated as targets (means
of fold enrichment, n= 4). d–e WEL028 reduces phagocytic uptake in FESS700C but not WT neutrophils. Treatment as in (a)–(b), followed by addition of
GFP-expressing E. coli B834 (MOI= 30, 1 h, 37 °C) and flow cytometry analysis (n= 5). Phagocytic index: fraction GFP-positive cells (number of
phagocytic cells) multiplied by GFP MFI (number of phagocytized bacteria). f SYK Y352 as proposed FES phosphorylation site (bold red), based on
phosphorylation of homologous ZAP70 peptide (PamChip® microarray, n= 3). g FES phosphorylates SYK Y352 in situ. U2OS cells co-expressing FESS700C-
FLAG and SYK-V5 were incubated with vehicle or WEL028 (200 nM, 1 h). Lysates were labeled (250 nM WEL033) and analyzed by in-gel fluorescence
and immunoblot (n= 3). h SYK interacts with FES. Co-transfected U2OS cells were incubated as in (g), followed by anti-FLAG immunoprecipitation and
immunoblot analysis (n= 3). i Phagocytosis of E. coli by HL-60 neutrophils depends on FES, SYK and PLCγ2 activity and actin polymerization. Incubations
as in (d)–(e) (WEL028: 100 nM, R406: 1 µM, U-73122: 5 µM, cytochalasin D: 10 µM; n= 5). j Phosphorylation of SYK Y352 and downstream substrates is
inhibited by WEL028 in infected FESS700C but not WT neutrophils, and absent in FESKO neutrophils. Inhibitor incubations as in (d)-(e), followed by
addition of GFP-expressing E. coli B834 (MOI= 30, 2 min, 37 °C) and immunoblot analysis (n= 3). Data represent means ± SEM. Statistical analysis:
ANOVA with Holm-Sidak’s multiple comparisons correction: ***P < 0.001; *P < 0.05; NS if P > 0.05. Source data are provided as Source Data file.
Fig. 8 Proposed model for the role of FES in neutrophil phagocytosis via SYK-HS1-PLCγ2 pathway activation. Representations are simplified for
illustration purposes.
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(e.g. proliferation, differentiation, and phagocytosis). Targeted
sequencing experiments further confirmed minimal transcrip-
tional differences (0.03% of read transcripts) between the clonal
FESS700C cell line and parental WT cell line. Although the low
efficiency of HDR-mediated mutagenesis did not allow us to
identify more than one homozygous mutant clone, recent
developments in CRISPR/Cas9 gene editing, base editing59 and
prime editing60 will undoubtedly improve this efficiency in the
future.
Our chemical genetics strategy allows temporal control in
modulating kinase activity, opposed to conventional genetic
approaches. In this report, we leverage this advantage by inacti-
vating FES activity both during myeloid differentiation and in
terminally differentiated neutrophils. In contrast to previous
studies relying on overexpression of (constitutively active) FES or
genetic knockout, we found that FES activity is dispensable for
differentiation towards macrophages in HL-60 cells. These results
are in line with two previous studies using genetic mouse
models17,61. Caution should thus be taken when using over-
expression systems, especially in case of artificial mutant kinases
with constitutive activity, as these may induce artefacts in cellular
physiology. It remains to be investigated whether FES plays a role
in myeloid differentiation into other cell types, or independently
of its kinase activity, e.g. as an interaction partner for other
proteins.
We illustrated that comparative target engagement profiling in
mutant and WT cells is a powerful approach to distinguish on-
target from off-target effects. Our results highlight the relevance
of visualizing target engagement to select a dose that is sufficient
to completely inactivate the kinase of interest, and avoid doses
that induce off-target effects. For example, differentiation of HL-
60 cells was prevented at a higher concentration of WEL028 than
required for complete FES inhibition. Chemical proteomics
identified various members of the MAP kinase family as off-
targets under these conditions. Interestingly, MAPK1/3 and
MAP2K1/2 are reported to be essential for HL-60 cell differ-
entiation along the monocyte/macrophage lineage47.
Our chemical genetics strategy revealed a biological role for
FES in neutrophils. Our data suggest that FES plays a role in the
phagocytic uptake of bacteria in neutrophils by activating SYK
and downstream substrates HS1 and PLCγ2. These data are in
line with previous studies that reported a role for FES in reg-
ulating surface expression of adhesion molecule PSGL-1 in leu-
kocytes21 and TLR4 during bacterial phagocytosis by peritoneal
macrophages52 In combination with data reported in the litera-
ture (reviewed in ref. 11), we can propose the following model
(Fig. 8 and Supplementary Discussion). One of the first events in
response to bacterial recognition by surface receptors is the for-
mation of phosphatidylinositol 4,5-bisphosphate (PIP2) in the
membrane (Fig. 8a)62. FES normally resides in the cytosol in an
inactive conformation, but translocation to the PIP2-rich mem-
brane may occur by binding via its F-BAR domain19. This likely
triggers the formation of oligomers and auto-activation by
phosphorylation on FES Y71310 and induces membrane curva-
ture required for particle internalization (Fig. 8b)63. FES may
subsequently activate SYK by phosphorylation of Y352 (or per-
haps indirectly via another kinase), which poses an alternative
activation mechanism of SYK compared to the traditional acti-
vation via binding to ITAM domains of immunoreceptors64,65.
SYK is known to phosphorylate HS1, an actin-binding protein
involved in reorganization of the actin cytoskeleton. It can be
phosphorylated on multiple tyrosine residues that all contribute
to its actin remodeling function66. Of note, its Y378 and Y397
residues are phosphorylated by FES in mast cells, but both sites
have also been identified as substrate sites for other kinases,
including SYK19. Phosphorylation of HS1 by FES and/or SYK
drives reorganization of the actin cytoskeleton required for
internalization of the bacterium-receptor complex (Fig. 8c).
Concomitantly, the phosphorylated Y352 residue in SYK could
serve as binding site for the SH2 domain of PLCγ2, followed by
SYK-mediated PLCγ2 activation67. In turn, this would allow for
degradation of PIP2 into diacylglycerol (DAG) and inositol-
triphosphate (IP3), altering the membrane composition62 and
returning it to the non-activated state: FES dissociates from the
membrane and the signaling process is terminated (Fig. 8d). This
model thus proposes a feedback mechanism in which FES
indirectly regulates its own localization and activation by mod-
ulating PLCγ2 activity via SYK.
Although we demonstrate that our strategy employing DFG-1
cysteine mutants can be applied to kinases other than FES
(Supplementary Note 1), it is unlikely that complete kinome
coverage can be achieved with a single chemotype of com-
plementary probes. Structural information of the target of interest
will facilitate the design of other complementary probe-protein
pairs. It should be noted that application of this chemical genetic
toolbox on other kinases should be accompanied by biochemical
characterization of the corresponding mutant kinase to verify that
its function is not affected. Consequently, it is important to
confirm that CRISPR/Cas9-generated mutant cells behave simi-
larly to WT cells in any employed downstream functional assays.
Finally, the selectivity acquired by combining gene editing and
a complementary probe brings the advantages of acute, phar-
macological inhibition without the need for extensive hit opti-
mization programs to identify compounds of adequate potency
and selectivity. Although we provided a proof of concept using a
cell line as model system, tremendous advancements in gene
editing technologies also provide means to generate mutant
(stem) cells or animal models. In conclusion, we envision that the
presented methodology could provide powerful pharmacological
tools to study the target engagement and function of poorly
characterized kinases and aid in their validation as therapeutic
targets.
Methods
Materials. All chemicals were purchased at Sigma Aldrich, unless stated otherwise.
DNA oligos were purchased at Sigma Aldrich or Integrated DNA Technologies and
sequences can be found in Supplementary Table 7. Cloning reagents were from
Thermo Fisher. TAE684 and R406 were purchased at Selleckchem and Cytocha-
lasin D and U-73122 at Focus Biomolecules. Cy5-azide and BODIPY-azide were
previously synthesized in-house and characterized by NMR and LC-MS. All cell
culture disposables were from Sarstedt. Bacterial and eukaryotic protease inhibitor
cocktails were obtained from Amresco.
Cloning. Full-length human cDNA encoding FES and PAK4 was obtained from
Source Bioscience. pDONR223-constructs with full-length human cDNA of FER,
LYN, PTK2 and SYK were a gift from William Hahn & David Root (Addgene
Human Kinase ORF Collection). For bacterial expression constructs, human FES
cDNA encoding residues 448–822 or human FER cDNA encoding residues
448–820 was amplified by PCR and cloned into expression vector pET1a in frame
of an N-terminal His6-tag and Tobacco Etch Virus (TEV) recognition site.
Eukaryotic expression constructs of FES, FER and PAK4 were generated by PCR
amplification and restriction/ligation cloning into a pcDNA3.1 vector, in frame of a
C-terminal FLAG-tag. Eukaryotic expression constructs of LYN, PTK2 and SYK
were generated using Gateway™ recombinational cloning into a pcDest40 vector, in
frame of a C-terminal V5-tag, according to recommended procedures (Thermo
Fisher). Point mutations were introduced by site-directed mutagenesis and all
plasmids were isolated from transformed XL-10 competent cells (prepared using E.
coli transformation buffer set; Zymo Research) using plasmid isolation kits fol-
lowing the supplier’s protocol (Qiagen). All sequences were verified by Sanger
sequencing (Macrogen).
For CRISPR/Cas9 plasmids, guides were cloned into the BbsI restriction site of
plasmid px330-U6-Chimeric_BB-CBh-hSpCas9 (gift from Feng Zhang, Addgene
plasmid #42230).
Protein expression and purification. Bacterial expression constructs were trans-
formed into E. coli BL21(DE3) co-transformed with a pCDFDuet-1 vector
encoding Yersinia phosphatase YopH (kindly provided by prof. dr. Kuriyan). Cells
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were grown in Luria Broth (LB) medium containing 50 µg/mL kanamycin and 50
μg/mL streptomycin at 37 °C to an OD600 of 0.4. The cultures were cooled on ice
and protein expression was induced by addition of 50 μM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 16 h at 18 °C. Cultures (typically 10 mL per
mutant) were centrifuged (1000g, 10 min, 4 °C) and washed in 1 mL physiological
salt solution (0.9% (w/v) NaCl). The pellet was then resuspended in 400 μL lysis
buffer (100 mM NaH2PO4 pH 8.0, 500 mM NaCl, 10% glycerol, 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP), 20 mM imidazole, 1 x bacterial protease inhibitor
cocktail) and cells were lysed by sonication on ice (15 cycles of 4″ on, 9.9″ off at
25% maximum amplitude; Vibra Cell (Sonics)). MgCl2 and OmniCleave (Epi-
centre) were added to final concentrations of 10 mM and 125 U/mL, respectively,
and lysates were incubated for 10 min at rt. Meanwhile, 200 μL Nickel Magnetic
Beads (BiMake), were homogenized by vortexing and washed in lysis buffer (3 ×
200 μL) using a magnetic separator. Lysate was added to beads and incubated for 1
h at 4 °C with vigorous shaking. Beads were then washed with lysis buffer con-
taining 75 mM imidazole (3 × 400 μL), after which the beads were transferred to a
clean Eppendorf tube. Protein was phosphorylated on beads by addition of
autophosphorylation buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol,
10 mM dithiothreitol (DTT), 10 mM Na3VO4, 2 mM (NH4)2SO4, 10 mM MgCl2, 5
mM MnCl2, 2 mM ATP) and vigorous shaking for 2 h at rt. Beads were subse-
quently washed with lysis buffer containing 20 mM imidazole (3 × 400 μL), after
which the protein was eluted in lysis buffer containing 250 mM imidazole (2 × 200
μL). The elution fractions were combined, applied onto a 10 kDa cutoff centrifugal
filter unit (Amicon) and centrifuged (14,000g, 10 min, 4 °C). The retentate was
reconstituted in 100 μL protein storage buffer (10 mM HEPES pH 7.5, 500 mM
NaCl, 5% glycerol, 10 mM DTT), aliquoted and stored at −80 °C. Protein con-
centration was measured using Qubit fluorometric quantitation (Thermo Fisher)
and protein purity was monitored by SDS-PAGE and Coomassie staining.
In vitro TR-FRET kinase assay. Assays were performed in white ProxiPlate-384
Plus™ 384-well microplates (Perkin Elmer). Incubation steps were performed at 21 °C
in kinase reaction buffer (50mM HEPES pH 7.5, 150mM NaCl, 10mM MgCl2,
1 mM EGTA, 2mM DTT, 0.01% Tween-20). Purified proteins were diluted in kinase
reaction buffer prior to use. All measurements were performed in triplicate.
Plates were read on a TECAN Infinite M1000 Pro plate reader, using
fluorescence top reading settings (λex= 320/20 nm, λem,donor= 615/10 nm, λem,
acceptor= 665/10 nm, 100 μs integration time, 50 μs lag time). Emission ratios were
calculated as fluorescence of acceptor / fluorescence of donor. Z′-factors were
determined for each individual assay plate as Z′= 1–3(σpc+ σnc)/(μpc − μnc), with
σ= standard deviation and μ=mean of measured replicates, WT or untreated
samples as positive control (pc) and samples incubated with no ATP as negative
control (nc). All plates met the requirement of Z′ > 0.7. Emission ratios were
corrected for background signal of samples incubated with no ATP. Corrected
ratios were averaged and normalized to WT or untreated signal as 100% reference.
For relative activity determination of mutants, purified WT or mutant FES
(12.5 ng per well) or FER (5 ng per well) was incubated with 50 nM ULight-TK
peptide (Perkin Elmer) and 100 μM ATP for 60 min at 21 °C in a total volume of
10 μL. The reaction was quenched by addition of 10 μL development solution (20
mM EDTA, 4 nM Europium-anti-phosphotyrosine antibody (PT66, Perkin Elmer)
and incubated for 60 min before fluorescence was measured.
For KM determinations, assay was performed as described above, but with
variable ATP concentrations in a dilution series of 1 mM to 100 nM. For IC50
determinations, serial dilutions of inhibitor were prepared in DMSO, followed by
further dilution in kinase reaction buffer. The inhibitors were premixed with
peptide and ATP (5 μM final concentration, unless indicated otherwise), after
which WT or mutant kinase was added to initiate the reaction. The final DMSO
concentration during the reaction was 1%. KM and IC50 curves were fitted using
GraphPad Prism® 7/8 (GraphPad Software Inc.).
PamChip® microarray assays. Kinase activity profiles were determined using the
PamChip® 12 protein tyrosine (PTK) peptide microarray system (PamGene
International B.V., ‘s-Hertogenbosch, The Netherlands) according to the instruc-
tions of the manufacturer. Arrays were blocked with 2% BSA (30 µL, 15 min, 2
cycles/min) and washed three times with kinase assay buffer (50 mM Tris pH 7.5,
10 mM MgCl2, 1 mM EDTA, 2 mM DTT, 0.01% Brij-35, 7.5 µg/mL PY20-FITC
antibody (AbD Serotec/Bio-Rad). Sample input was 0.25 ng purified FES (WT or
S700C) per array and [ATP]= 400 µM. For arrays with inhibitor, recombinant FES
was preincubated in assay buffer without ATP with vehicle or WEL028 (100 nM,
30 min, on ice, 2% final DMSO concentration). Peptide phosphorylation was
monitored during the incubation with assay mixture, by taking images every 5 min
at 50 ms exposure time, allowing real time recording of the reaction kinetics (one-
step reaction). After washing of the array, fluorescence was detected at different
exposure times (20, 50, 100, and 200 ms).
For SH2 domain binding assays, PamChip® protein tyrosine kinase (PTK)
arrays were blocked by pumping a 2% BSA solution up and down through the
array (30 µL, 15 min, 2 cycles/min). After three washing steps, the arrays were pre-
phosphorylated by incubation with 1.5 pmol of (His6-tagged) JAK2 catalytic
domain for 60 cycles in kinase assay buffer with 0.01% BSA. After three washing
steps, the arrays were incubated with 0.75 ng of FES (WT or S700C) in PBS/0.1%
Tween supplemented with 0.01% BSA. Incubations without FES served as negative
control. After three washing steps, binding of FES was visualized by incubation
with Alexa Fluor 488 labeled anti-penta-His antibody (7.5 µg/mL final
concentration, Qiagen, #1019199) in PBS/0.01% Tween. Peptide phosphorylation
of JAK2 was detected with the same anti p-Tyr antibody as used in the PTK activity
assay. After incubation for 30 min (2 cycles/min), arrays were washed, and images
taken at different exposure times.
Data quantification of the images at all exposure times and reaction times and
visualization of the data were performed using the BioNavigator 6.3 software
(PamGene International B.V., ‘s-Hertogenbosch, The Netherlands). Post-wash
signals (local background subtracted) were used. After signal quantification and
integration of exposure times, signals were log2-transformed for visualization.
Peptides with no ATP-dependent signal were excluded from analysis. Identification
of peptides that were significantly different between conditions was performed
using a Mixed Model statistical analysis. Substrate consensus motif was generated
using Enologos (http://www.benoslab.pitt.edu).
Selectivity profiling. Selectivity profiling assays were performed by the Invitrogen
SelectScreen™ Services. A complete list of tested kinases can be found in Supple-
mentary Fig. 4, detailed assay procedures are described in SelectScreen Assay
Conditions documents located at www.invitrogen.com/kinaseprofiling. All kinases
were preincubated for 1 h at indicated concentrations of inhibitor. The con-
centration of ATP was selected to be equal to the KM, unless indicated otherwise.
An initial screen was performed on 279 kinases at single dose of 1 μM. All available
kinases with native cysteine residues in the active site were included in this panel.
Kinases showing >50% inhibition at 1 μM were further profiled in dose-response
experiments in a 10-point dilution series of 10 μM to 0.5 nM.
Docking studies. All structure-based modeling was performed in Schrödinger
Suite (version 2017-2, Schrödinger). The docking of compound 4 was based on the
crystal structure of FES co-crystallized with TAE684 (PDB: 4e93)28, which was
prepared by the protein preparation wizard. Prior to docking, the Ser700 residue
was manually changed into a cysteine. Subsequently, compound 4 was aligned to
TAE684 on the basis of the diaminopyrimidine (both ligands share the same
kinase/hinge binding moiety). This pose was optimized using an exhaustive hier-
archical optimization procedure available in Prime (version 2017-2, Schrödinger)68
The acrylamide warhead was found in proximity of Cys700 and the ligand was then
covalently attached to this residue, followed by another round of hierarchical
optimization68. Figures were rendered using PyMOL Molecular Graphics System
(version 1.8, Schrödinger).
MS identification of covalent inhibitor-peptide adduct. Purified FESS700C (1.2
μg in 38 μL) was treated with WEL028 (2 μL of 20× concentrated stock in DMSO,
1 μM final concentration) or vehicle (as negative control) for 30 min at rt. The
reaction was quenched by addition of 3× Laemmli buffer (20 μL), incubated for 5
min at 95 °C and sample (400 ng, 20 μL) was resolved on 10% acrylamide SDS-
PAGE gel (200 V, 60 min). Gel was stained using Coomassie Brilliant Blue R-250,
bands were cut out of gel into small blocks and then destained in 500 μL of 50%
MeOH in 100 mM NH4HCO3 pH 8.0 for 10 min at rt. Acetonitrile (500 μL) was
added for gel blocks dehydration, after which gel blocks were digested with
sequencing-grade trypsin (Promega) in 250 μL trypsin buffer (100 mM Tris pH 7.5,
100 mM NaCl, 1 mM CaCl2, 10% acetonitrile) overnight at 37 °C with vigorous
shaking. The pH was adjusted with formic acid to pH 3, after which the sample was
diluted in extraction solution (65% acetonitrile/35% MilliQ) and concentrated in a
SpeedVac concentrator. Samples were subsequently desalted using StageTips with
C18 material. Each StageTip was conditioned with MeOH (50 μl, 300g, 2 min),
followed by solution B (50 μl, 80% v/v acetonitrile, 0.5% v/v formic acid in MilliQ,
300g, 2 min) and solution A (50 μl, 0.5% v/v formic acid in MilliQ, 300g, 2 min).
Next, samples were loaded, centrifuged (300g, 2 min) and the peptides on the
StageTip were washed with solution A (100 μl, 300g, 2 min). The StageTips were
transferred to new 1.5 mL low-binding tubes and peptides were eluted with solu-
tion B (100 μl, 300g, 2 min). Solvents were evaporated to dryness in a SpeedVac
concentrator (45 °C, 3 h). Samples were reconstituted in LC-MS solution (50 μl, 3%
v/v acetonitrile, 0.1% v/v formic acid, 1 μM yeast enolase peptide digest (Waters,
186002325) in MilliQ).
Tryptic peptides were analyzed on a Surveyor nano-LC system (Thermo)
hyphenated to a LTQ-Orbitrap mass spectrometer (Thermo) (n= 1)69. Gold
and carbon coated emitters (OD/ID= 360/25 μm tip ID= 5 μm), trap column
(OD/ID= 360/100 μm packed with 25 mm robust Poros10R2/ 15 mm BioSphere
C18 5 μm 120 Å) and analytical columns (OD/ID= 360/75 μm packed with 20 cm
BioSphere C18 5 μm 120 Å) were from Nanoseparations (Nieuwkoop, The
Netherlands). The mobile phases (A: 0.1% formic acid/H2O, B: 0.1% formic acid/
acetonitrile) were made with ULC/MS grade solvents (Biosolve). The emitter tip
was coupled end-to-end with the analytical column via a 15 mm long TFE Teflon
tubing sleeve (OD/ID 0.3 × 1.58 mm, Supelco, USA) and installed in a stainless
steel holder mounted in a nano-source base (Upchurch scientific, Idex, USA).
General mass spectrometric conditions were: electrospray voltage of 1.8 kV, no
sheath and auxiliary gas flow, ion transfer tube temperature 150 °C, capillary
voltage 41 V, tube lens voltage 150 V. Internal mass calibration was performed
with polydimethylcyclosiloxane (m/z= 445.12002) and dioctyl phthalate ions
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(m/z= 391.28429) as lock mass. Samples of 10 µl were separated via a trap-elute
setup at 250 nL/min flow and analyzed by data-dependent acquisition of one full
scan/ top 3 method. For shotgun proteomics, fragmented precursor ions measured
twice within 10 s were dynamically excluded for 60 s and ions with z < 2 or
unassigned charges were not analyzed. Peptide ID was determined with the Mascot
search engine. A parent ion list of the m/z ratios of the active-site peptides was
compiled and used for LC-MS/MS analysis in a data-dependent protocol. The
parent ion (m/z [M+ 2H]2+ = 689.2671) was electrostatically isolated in the ion
trap of the LTQ and fragmented by MS/MS. Precursor ion was not observed in
vehicle-treated control. Data from MS/MS experiments were validated manually.
Inhibitor washout by dialysis. FESS700C-overexpressing HEK293T lysate (396 μL,
1.43 mg/mL) was incubated with vehicle, TAE684 or WEL028 (4 μL of 100x
concentrated stock in DMSO) at final concentrations corresponding to their
respective IC80 values (TAE684: 225 nM, WEL028: 231 nM) for 30 min at rt. One
fraction (200 μL) of the sample was immediately flash-frozen and stored at −80 °C
until use. The remaining sample was transferred to a dialysis cassette (Slide-A-
Lyzer™ Dialysis Cassette, 7K MWCO, 0.5 mL; Thermo Fisher), followed by dialysis
in 200 mL PBS overnight at 4 °C. Pre- and post-dialysis samples were then incu-
bated with probe WEL033 as described in the section “One-step probe labeling
experiments” below, or conjugated to BODIPY-N3 by CuAAC as described in the
section “Two-step probe labeling experiments” below.
Cell culture—general. Cell lines were purchased at ATCC (HEK293T: ATCC®
CRL-11268™, U2OS: ATCC® HTB-96™, HL-60: ATCC® CCL-240™) and were tested
on regular basis for mycoplasma contamination. Cultures were discarded after
2–3 months of use. HEK293T (human embryonic kidney) and U2OS (human
osteosarcoma) cells were cultured at 37 °C under 7% CO2 in DMEM containing
phenol red, stable glutamine, 10% (v/v) high iron newborn calf serum (Seradigm),
penicillin and streptomycin (200 μg/mL each; Duchefa). Medium was refreshed
every 2–3 days and cells were passaged two times a week at 80–90% confluence.
HL-60 (human promyeloblast) cells were cultured at 37 °C under 5% CO2 in
HEPES-supplemented RPMI containing phenol red, stable glutamine, 10% (v/v)
fetal calf serum (Biowest), penicillin and streptomycin (200 μg/mL each), unless
stated otherwise. Cell density was maintained between 0.2 × 106 and 2.0 × 106 cells/
mL. Cell viability was assessed by Trypan Blue exclusion and quantification using a
TC20™ Automated Cell Counter (Bio-Rad).
Cell culture—transfection. One day prior to transfection, HEK293T or U2OS cells
were transferred from confluent 10 cm dishes to 15 cm dishes. Before transfection,
medium was refreshed (13 mL). A 3:1 (m/m) mixture of polyethyleneimine (PEI;
60 μg/dish) and plasmid DNA (20 μg/dish) was prepared in serum-free medium
and incubated for 15 min at rt. The mixture was then dropwisely added to the cells,
after which the cells were grown to confluence in 72 h (HEK293T) or 48 h (U2OS).
Cells were then harvested by suspension in PBS, followed by centrifugation for 5
min at 200g. Cell pellets were flash-frozen in liquid nitrogen and stored at −80 °C
until sample preparation.
Transfection of CRISPR plasmid DNA and ssODN repair template into HL-60
cells was performed using Amaxa nucleofector kit V and nucleofector I device
(Lonza). One day prior to transfection, HL-60 cells were diluted to a density of 0.4
× 106 cells/mL. The next day, 2 × 106 cells per condition were centrifuged at 200g
for 5 min and resuspended in 100 μL nucleofection solution. Plasmid DNA (2 μg)
and if applicable ssODN repair template (400 pmol) were added and cells were
nucleofected using program T-019. Cells were allowed to recover for 10 min at rt
before transfer to 12-well plates and further recovery in antibiotics-free medium
at 37 °C.
Cell culture—differentiation. One day prior to induction of differentiation, cells
were diluted to 0.4 × 106 cells/mL. Monocyte/macrophage differentiation was
induced by addition of phorbol 12-myristate 13-acetate (PMA; 16 nM) for 48 h,
during which cells attached to the plastic surface and acquired monocyte/macro-
phage morphology. Neutrophil differentiation was induced by addition of all-trans-
retinoic acid (1 µM) and dimethylsulfoxide (1.25%) for 72–96 h. For morphological
inspection, images were taken on an EVOS FL Auto 2 Imaging System (Thermo
Fisher) at ×20 magnification.
Cell culture—inhibitor treatment. The term in situ is used to designate experi-
ments in which live cell cultures are treated with inhibitor, whereas the term
in vitro refers to experiments in which the inhibitor is incubated with cell lysates.
Compounds were diluted in growth medium from a 1000x concentrated stock
solution in DMSO. For in situ assays on live transfected cells, cells were transfected
prior to treatment as described above. After 48 h, cells were treated with compound
for 1 h. Cells were collected by suspension in PBS and centrifuged (1000g, 5 min,
rt). Pellets were flash-frozen in liquid nitrogen and stored at −80 °C until use. For
in situ treatment post-differentiation, HL-60 cells were differentiated as described
above and incubated with compound for 1 h unless specified otherwise. Cells were
collected by suspension for non-adherent cells and trypsinization for adherent cells.
After collection, cells were centrifuged (200g, 5 min, rt) and washed in equal
volume of PBS (1000g, 5 min, rt). Cell pellets were flash-frozen in liquid nitrogen
and stored at −80 °C until use.
CRISPR/Cas9 gene editing. Selection of sgRNA was based on proximity to
desired site of cleavage or mutagenesis as well as efficiency and specificity as
predicted by CHOPCHOP v2 online web tool (http://chopchop.cbu.uib.no).
sgRNA sequences can be found in Supplementary Table 7. For FES mutagenesis, a
sgRNA targeting exon 16 was selected and an ssODN HDR donor was designed
that after successful HDR incorporates the desired S700C mutation along with a
BglII restriction site to facilitate analysis by RFLP. Furthermore, silent mutations
are incorporated to remove “NGG” protospacer-adjacent motifs (PAMs), pre-
venting recleavage of the genomic sequence after successful HDR or cleavage of the
ssODN donor itself. For FES knockout, a sgRNA targeting exon 1 was selected.
For preparation of conditioned RPMI medium, HL-60 cells were diluted to 0.2
× 106 cells/mL and grown for 48 h at 37 °C. Cell suspension was then centrifuged
(1000g, 5 min) and medium was transferred to a clean tube, followed by a second
centrifugation step (3500g, 10 min). The medium was subsequently filtered through
a 0.2 μm sterile filter and stored at −80 °C until use, for no longer than 3 months.
Single cell cultures were obtained approximately 7 days post-nucleofection by
dilution in 1:1 conditioned and fresh RPMI medium and expanded in 96-well
plates (100 μL per well). After 14 days, plates were inspected for cell growth, clones
were collected in new plates and half of the volume was transferred to 96-well PCR-
plates, followed by centrifugation (1000g, 10 min). Medium was removed and cell
pellets were suspended in 25 μL QuickExtract™ (Epicentre). The samples were
incubated at 65 °C for 6 min, mixed by vortexing and then incubated at 98 °C for 2
min. Genomic DNA extracts were diluted in sterile water and directly used in PCR
reactions. Genomic PCR reactions were performed on 5 μL isolated genomic DNA
extract using Phusion High-Fidelity DNA Polymerase (Thermo Fisher) in Phusion
HF buffer in a final volume of 20 μL.
Genotyping assays. Restriction fragment length polymorphism (RFLP) assays
were performed by combining genomic PCR product (8.5 μL) with FastDigest
buffer (1 μL) and FastDigest BglII (0.5 μL; Thermo Fisher), followed by incubation
at 37 °C for 30 min.
For T7E1 assays, genomic PCR products were mixed in a 1:1 ratio with WT
amplicons and denatured and reannealed in a thermocycler using the following
program: 5 min at 95 °C, 95 to 85 °C using a ramp rate of −2 °C/s, 85 to 25 °C using
a ramp rate of −0.2 °C/s. To annealed PCR product (8.5 μL), NEB2 buffer (1 μL)
and T7 endonuclease I (5 U, 0.5 μL; New England Biolabs) were added, followed by
incubation at 37 °C for 30 min. Digested PCR products were analyzed using
agarose gel electrophoresis with ethidium bromide staining.
For sequencing analysis, genomic PCR products were purified using
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel), followed by Sanger
sequencing. For knockouts, sequence traces were decomposed using the TIDE
online web tool (www.deskgen.com). The efficiency for obtaining homozygous
mutant clones was approximately 0.5–1% (typically 1 out of 100–200 clones),
whereas the efficiency of obtaining full knockout clones was approximately 10%.
Potential off-target cleavage sites of the used sgRNA were predicted using
DESKGEN™ online web tool (www.deskgen.com). Top-ranked potential coding off-
target sequences containing three or less mismatches to the employed sgRNA
sequence were selected for validation. The genomic region surrounding the
potential off-target site was amplified by PCR and analyzed by Sanger sequencing.
Preparation of cell lysates. Pellets of HEK293T or U2OS cells were thawed on ice
and suspended in lysis buffer (50 mM HEPES pH 7.2, 150 mM NaCl, 1 mM MgCl2,
0.1% (w/v) Triton X-100, 2 mM Na3VO4, 20 mM NaF, 1 x mammalian protease
inhibitor cocktail, 25 U/mL benzonase). Cells were lysed by sonication on ice (15
cycles of 4″ on, 9.9″ off at 25% maximum amplitude). Protein concentration was
determined using Quick Start™ Bradford Protein Assay (Bio-Rad) and diluted to
appropriate concentration in dilution buffer (50 mM HEPES pH 7.2, 150 mM
NaCl). Lysates were aliquoted, flash-frozen and stored at −80 °C until use.
Pellets of HL-60 cells were thawed on ice and suspended in M-PER buffer
supplemented with 1x Halt™ phosphatase and protease inhibitor cocktail (Thermo
Fisher), followed by centrifugation (14,000g, 10 min, 4 °C). The resulting clear
lysate was further processed as described above.
One-step probe labeling experiments. For in vitro inhibition experiments, cell
lysate (14 μL) was preincubated with inhibitor (0.5 μL, 29 × concentrated stock in
DMSO, 30 min, rt), followed by incubation with WEL033 (0.5 μL, 30 × con-
centrated stock in DMSO, 30 min, rt). For in situ inhibition experiments, treated
cell lysate (14.5 μL) was directly incubated with WEL033 (0.5 μL, 30 × concentrated
stock in DMSO, 30 min, rt). Final concentrations of inhibitors and/or WEL033 are
indicated in the main text and figure legends. Reactions were quenched with 4×
Laemmli buffer (5 μL, final concentrations 60 mM Tris pH 6.8, 2% (w/v) SDS, 10%
(v/v) glycerol, 5% (v/v) β-mercaptoethanol, 0.01% (v/v) bromophenol blue) and
boiled for 5 min at 95 °C. Samples were resolved on 10% acrylamide SDS-PAGE gel
(180 V, 75 min). Gels were scanned using Cy3 and Cy5 multichannel settings (605/
50 and 695/55 filters, respectively; ChemiDoc™ MP System, Bio-Rad). Fluorescence
intensity was corrected for protein loading determined by Coomassie Brilliant Blue
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R-250 staining and quantified with Image Lab (Bio-Rad). IC50 curves were fitted
with Graphpad Prism® 7/8 (Graphpad Software Inc.).
Two-step probe labeling experiments. For in vitro experiments, cell lysate (12
μL) was preincubated with inhibitor (0.5 μL, 25× concentrated stock in DMSO, 30
min, rt), followed by incubation with WEL028 (0.5 μL, 26× concentrated stock in
DMSO, 30 min, rt). Meanwhile, “click mix” was prepared freshly by combining
CuSO4 (1 μL of 15 mM stock), sodium ascorbate (0.6 μL of 150 mM stock), THPTA
(0.2 μL of 15 mM stock) and fluorophore-azide (0.2 μL of 150× concentrated stock
in DMSO, 2 eq.). Click mix was added to the reaction, followed by incubation for
30 min at rt, after which the reaction was quenched and further processed as
described above. For in situ inhibition experiments, WEL028-treated cells were
lysed and directly incubated with click mix.
Chemical proteomics. Cell lysates of FESWT and FESS700C HL-60 macrophages or
neutrophils incubated in situ with WEL028 or vehicle (as negative control) were
prepared as aforementioned (n= 3 or 4 biological replicates). Lysates (250 μL of 2
mg/mL) were conjugated to biotin-azide using click chemistry (25 μL click mix, 1 h,
37 °C). The reaction was quenched and excess biotin-azide was removed by
chloroform/methanol precipitation. Precipitated proteome was suspended in 6M
urea in 25 mM ammonium bicarbonate, reduced (10 mM DTT, 15 min, 65 °C) and
alkylated (40 mM iodoacetamide, 30 min, rt, in the dark). SDS was added (2% final
concentration, 5 min, 65 °C), samples were diluted in PBS and incubated with
avidin beads (from 50% slurry, 3 h, rt, in overhead rotator). Beads were washed
with 0.5% SDS in PBS, followed by 3 washes with PBS, and then transferred to low-
binding Eppendorf tubes. Proteins were digested with trypsin overnight at 37 °C
and resulting peptides were desalted using stage tips with C18 material as described
in the section “MS identification of covalent inhibitor-peptide adduct” above.
The peptides were measured on a NanoACQUITY UPLC System coupled to
SYNAPT G2-Si high definition mass spectrometer69. A trap-elute protocol, where
5 μL of the digest was loaded on a trap column (C18 100 Å, 5 μm, 180 μm × 20mm,
Waters) followed by elution and separation on the analytical column (HSS-T3 C18
1.8 μm, 75 μm × 250 mm, Waters). The sample was brought onto this column at a
flow rate of 10 μL/min with 99.5% solvent A (0.1% formic acid/H2O) for 2 min
before switching to the analytical column. Peptide separation was achieved using a
multistep concave gradient. The column was re-equilibrated to initial conditions
after washing with 90% solvent B (0.1% formic acid/acetonitrile). The rear seals of
the pump were flushed every 30 min with 10% (v/v) acetonitrile. [Glu1]-
fibrinopeptide B (GluFib) was used as a lock mass compound. The auxiliary pump
of the LC system was used to deliver this peptide to the reference sprayer (0.2 μL/
min). The mass range was set from 50 to 2000 Da with a scan time of 0.6 s in
positive, resolution mode. The collision energy was set to 4 V in the trap cell for
low-energy MS mode. For the elevated energy scan, the transfer cell collision
energy was ramped using drift-time specific collision energies. The lock mass was
sampled every 30 s. For raw data processing, PLGS (version 3.0.3) was used. The
MSE identification workflow was performed to search the human proteome from
Uniprot (uniprot-homo-sapiens-trypsin-reviewed-2016_08_29.fasta). Protein
quantification was performed using ISOQuant (version 1.5). Relevant data
processing parameters are found in Supplementary Table 8 and 969.
The following cut-offs were used for target identification: unique peptides ≥ 1,
identified peptides ≥ 2, ratio WEL028-treated over vehicle-treated ≥ 2 with q-value
< 0.05 based on t-test with Benjamini-Hochberg multiple comparison correction
(FDR= 10%), kinase annotation in Uniprot database.
Immunoblot. Samples were resolved by SDS-PAGE as described above, but
transferred to 0.2 μm polyvinylidene difluoride membranes by Trans-Blot Turbo™
Transfer system (Bio-Rad) directly after fluorescence scanning. Membranes were
washed with TBS (50 mM Tris pH 7.5, 150 mM NaCl) and blocked with 5% milk in
TBS-T (50 mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween-20) for 1 h at rt.
Membranes were then incubated with primary antibody in 5% milk in TBS-T
(FLAG, V5, β-actin; o/n at 4 °C) or washed three times with TBS-T, followed by
incubation with primary antibody in 5% BSA in TBS-T (other antibodies, o/n at
4 °C). Membranes were washed three times with TBS-T, incubated with matching
secondary antibody in 5% milk in TBS-T (1:5000, 1 h at rt) and then washed three
times with TBS-T and once with TBS. Luminol development solution (10 mL of
1.4 mM luminol in 100 mM Tris pH 8.8+ 100 µL of 6.7 mM p-coumaric acid in
DMSO+ 3 µL of 30% (v/v) H2O2) or Clarity Max™ ECL Substrate (Bio-Rad) was
added and chemiluminescence was detected on ChemiDoc™ MP System.
Following detection of phospho-proteins, membranes were stripped (Restore™
Plus Stripping Buffer, Thermo Fisher) for 20 min, washed three times with TBS,
and blocked and incubated with the control antibodies as described above.
Primary antibodies: monoclonal mouse anti-FLAG M2 (1:5000, Sigma Aldrich,
F3156), monoclonal anti-V5 (1:5000, Thermo Fisher, R960–25), monoclonal
mouse anti-β-actin (1:1000, Abcam, ab8227), polyclonal rabbit anti-Lamin B1
(1:5000, Thermo Fisher, PA5-19468), polyclonal rabbit anti-phospho-FES Y713
(1:1000, Thermo Fisher, PA5-64504), monoclonal rabbit anti-FES (1:1000, Cell
Signaling Technology (CST), #85704), polyclonal rabbit anti-phospho-SYK Y352
(1:1000, CST, #2701), monoclonal rabbit anti-SYK (1:1000, CST, #13198),
polyclonal rabbit anti-phospho-HS1 Y397 (1:1000, CST, #4507), polyclonal rabbit
anti-HS1 (1:1000, CST, #4503), polyclonal rabbit anti-phospho-PLCγ2 Y1217
(1:1000, CST, #3871), polyclonal rabbit anti-PLCγ2 (1:1000, CST, #3872).
Secondary antibodies: goat anti-mouse-HRP (1:5000, Santa Cruz, sc-2005), goat
anti-rabbit-HRP (1:5000, Santa Cruz, sc-2030).
CD11b expression analysis by flow cytometry. Cells (1 × 106 per sample) were
centrifuged (500g, 3 min) and suspended in human FcR blocking solution (Miltenyi
Biotec, 25× diluted in FACS buffer (1% BSA, 1% FCS, 0.1% NaN3, 2 mM EDTA in
PBS)), transferred to a V-bottom 96-well plate and incubated for 10 min at 4 °C.
Next, monoclonal rat CD11b-APC antibody (1:100, Miltenyi Biotec, 130-113-231)
or rat anti-IgG2b-APC isotype control antibody (1:100, Miltenyi Biotec, 130-106-
728) was added along with 7-AAD (1 µg/mL) and samples were incubated for 30
min 4 °C in the dark. Samples were washed once in PBS and fixed in 1% PFA in
PBS for 15 min at 4 °C in the dark, followed by two washing steps in PBS and
resuspension in FACS buffer to a density of approximately 500 cells/μL. Cell
suspensions were measured on a Guava easyCyte HT and data was processed using
GuavaSoft InCyte 3.3 (Merck Millipore). Events (generally 20,000 per condition)
were gated by forward and side scatter (cells), side scatter area (singlets) and
viability (live cells) and the percentage of CD11b-positive cells was determined
based on background fluorescence for isotype control antibody and non-
differentiated cells. The RED-R channel (661/15 filter) and RED-B channel (695/50
filter) were used to detect CD11b-APC and 7-AAD, respectively.
Neutrophil oxidative burst assay. Cells were centrifuged (500g, 3 min), sus-
pended in PBS and seeded in triplicate per condition in 96-well plates (100,000 cells
per well in 100 µL). To each well, 100 µL of PBS containing nitroblue tetrazolium
(NBT) with vehicle or PMA was added, bringing final concentrations to 0.1% and
1.6 µM, respectively. Cells were incubated (1 h, 37 °C) and plates were imaged by
phase contrast microscopy (20x magnification, EVOS FL Auto 2). Cells positive for
formazan deposits were counted (three different fields per replicate).
TempO-Seq transcriptome profiling. HL-60 cells were seeded at 20,000 cells per
well in a 96-well plate and differentiated towards macrophages as aforementioned
with three independent biological replicates. After 48 h, medium was removed, cells
were washed with 100 µL PBS and subsequently lysed in 50 µL 1x BioSpyder lysis
buffer (15 min, rt). Lysates were flash-frozen in liquid nitrogen, stored at −80 °C
and shipped to BioSpyder technologies on dry ice, where the TempO-Seq® pro-
filing was conducted according to supplier’s standard procedures48. Raw gene
transcription counts were subjected to internal normalization using DESeq2 and
statistical significance determined by t-test with Benjamini-Hochberg multiple
comparison correction (FDR= 1%). Differentially expressed genes were identified
using following cut-offs: fold change of corrected counts of FESS700C over WT HL-
60 cells < 0.5 or >2 with q-value < 0.05.
Co-immunoprecipitation. U2OS cells were co-transfected with FLAG-tagged FES
and V5-tagged SYK and grown for 48 h as described above, followed by incubation
with vehicle or WEL028 (200 nM) for 1 h. Cells were then washed with PBS and
collected by scraping in IP-buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1%
Triton X-100 supplemented with 1g Halt™ phosphatase and protease inhibitor
cocktail (Thermo Fisher)). Cells were lysed by sonication on ice (three cycles of 10′′
on, 10′′ off at 25% maximum amplitude), centrifuged (14,000g, 10 min, 4 °C). The
clear lysate was diluted to 1 mg/mL in IP-buffer and subjected to immunopreci-
pitation using Dynabeads™ Protein G Immunoprecipitation kit (Thermo Fisher)
following manufacturer’s protocol. Briefly, anti-FLAG M2 antibody (1:100, Sigma
Aldrich, F3156) was incubated with beads with gentle rotation (10 min, rt), after
which lysate (500 µL of 1 mg/mL) was added and incubated (1 h, 4 °C). Beads were
washed three times, transferred to clean tubes and eluted by suspension in 2×
Laemmli buffer (50 µL, 10 min, 70 °C). Samples (10 µL per lane) were resolved by
SDS-PAGE and immunoblotted using anti-V5 or anti-FLAG antibodies. Immu-
noprecipitations were performed in three independent replicates.
Phagocytosis assay. HL-60 cells were differentiated to neutrophils as described
above. Cells were counted and centrifuged (200g, 5 min), followed by resuspension
in growth medium without antibiotics. Cells were incubated with vehicle or inhi-
bitor (from 1000x concentrated stocks in DMSO) for 1 h at 37 °C prior to infection
(1×106 cells in 900 µL in 12-well plate). Meanwhile, E. coli B834(DE3) con-
stitutively expressing GFPA206K were grown in LB medium to an OD600 of 0.4–1.0,
after which bacteria were centrifuged (2000g, 5 min), washed and resuspended in
PBS to appropriate density70. Neutrophils were infected by addition of bacteria at
multiplicity of infection (MOI) of 30 unless stated otherwise. Cells were then
incubated for 1 h at 37 °C unless stated otherwise, after which cells were resus-
pended and transferred to Eppendorf tubes, washed in FACS buffer (1 mL, 500g, 3
min) and fixed in 1% PFA in PBS (15 min, 4 °C, in the dark). Samples were further
processed as described above.
Events (generally 20,000 per condition) were gated by forward and side scatter
(cells), side scatter area (singlets) and the percentage of GFP-positive cells and GFP
mean fluorescence intensity (MFI) were determined based on background
fluorescence for non-infected cells. The GREEN-B channel (525/30 filter) was used
to detect GFP. Phagocytic index was calculated as fraction of GFP-positive cells
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(number of phagocytic cells) multiplied by GFP MFI (number of phagocytized
bacteria).
Neutrophil stimulation and phosphoprotein analysis. HL-60 neutrophils were
infected as described above, but in 1.5 mL tubes (5 × 106 cells per sample, in 1 mL
growth medium without antibiotics, supplemented with FcR blocking reagent
(1:25)). After indicated infection times, suspensions were immediately centrifuged
(2000g, 2 min, 4 °C). Supernatant was completely aspirated and cells were washed
(1 mL cold PBS, 2000g, 2 min, 4 °C). Pellets were thoroughly resuspended in 1×
Laemmli sample buffer (75 µL), followed by incubation at 95 °C (15 min, 1400 rpm)
and brief sonication to reduce sample viscosity. Samples were stored at −20 °C or
immediately resolved by SDS-PAGE.
Statistics and reproducibility. All statistical measures and methods are included
in the respective figure or table captions. In brief: all replicates represent biological
replicates and all data represent means ± SEM, unless indicated otherwise. Sta-
tistical significance was determined using Student’s t tests (two-tailed, unpaired) or
ANOVA with Holm-Sidak’s multiple comparisons correction. ***P < 0.001; **P <
0.01; *P < 0.05; NS if P > 0.05. All statistical analyses were conducted using
GraphPad Prism® 7/8 or Microsoft Excel.
Reproducibility of experiments was confirmed by the use of separately
measured (biological) replicates and/or appropriate controls. In vitro biochemical
and cellular experiments (including results presented in Figs. 4b, c, 5c–h and
Supplementary Figs. 6a–c, 7a and 9h) were performed at least in two independent
experiments, yielding similar results. For quantified data, the exact number of
replicates per data point is indicated in figure legends.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 2–7, Table 1, Supplementary Figs. 1–2, 4–9 and 12–18
and Supplementary Tables 2–4 are provided as a Source Data file. Other data are
available from authors upon request.
The TempO-Seq data associated with Fig. 5g are available online in the Gene
Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov). The GEO
accession number is GSE145811.
The proteomics data associated with Fig. 6f-g and Fig. 7c are available online in the
Proteomics Identifications Database (PRIDE) (https://www.ebi.ac.uk/pride). The PRIDE
dataset identifier is PXD018270. Substrate consensus motif was generated using Enologos
(http://www.benoslab.pitt.edu). The DESKGEN™ (www.deskgen.com) and CHOPCHOP
v2 (http://chopchop.cbu.uib.no) online web tools were used for CRISPR design and
analyses. Uniprot databases were used for proteomics analyses (https://www.uniprot.org/
proteomes). Source data are provided with this paper.
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